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Background: The eradication of large, established tumors by active immunotherapy is a major challenge because
of the numerous cancer evasion mechanisms that exist. This study aimed to establish a novel combination therapy
consisting of messenger RNA (mRNA)-based cancer vaccines and radiation, which would facilitate the effective
treatment of established tumors with aggressive growth kinetics.
Methods: The combination of a tumor-specific mRNA-based vaccination with radiation was tested in two
syngeneic tumor models, a highly immunogenic E.G7-OVA and a low immunogenic Lewis lung cancer (LLC). The
molecular mechanism induced by the combination therapy was evaluated via gene expression arrays as well as
flow cytometry analyses of tumor infiltrating cells.
Results: In both tumor models we demonstrated that a combination of mRNA-based immunotherapy with
radiation results in a strong synergistic anti-tumor effect. This was manifested as either complete tumor eradication
or delay in tumor growth. Gene expression analysis of mouse tumors revealed a variety of substantial changes at
the tumor site following radiation. Genes associated with antigen presentation, infiltration of immune cells,
adhesion, and activation of the innate immune system were upregulated. A combination of radiation and
immunotherapy induced significant downregulation of tumor associated factors and upregulation of tumor suppressors.
Moreover, combination therapy significantly increased CD4+, CD8+ and NKT cell infiltration of mouse tumors.
Conclusion: Our data provide a scientific rationale for combining immunotherapy with radiation and provide a basis for
the development of more potent anti-cancer therapies.
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Despite recent advances in the field of cancer immuno-
therapy, the treatment of large, advanced tumors re-
mains very challenging and the clinical outcome is often
disappointing [1,2]. There are some encouraging clinical
results, however, which show that combining targeted
therapies (e.g. EGFR inhibitors, anti-angiogenic agents,
vaccines) with local radiation can result in an improved
clinical outcome. Because of our experience in mRNA-
based cancer vaccine development we sought to deter-
mine if mRNA immunotherapy and local tumor radiation
could act synergistically to inhibit the growth of large,* Correspondence: mf@curevac.com
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article, unless otherwise stated.established tumors. Next, we asked if combined immuno-
radiotherapy could also inhibit the growth of low immuno-
genic tumors such as Lewis lung cancer (LLC). Finally, to
get an insight into the mechanisms involved, we looked at
cellular and molecular changes at the tumor sites following
combination therapy.
Different strategies for combined anti-tumor therapy
have already been tested. Among these approaches,
which include chemotherapy, small molecule inhibitors
and monoclonal antibodies, radiation therapy is the most
interesting candidate for combining with active immuno-
therapy. Not only can radiation destroy tumor cells, it can
also induce substantial changes in the tumor microenviron-
ment. The effects of radiation differ over time and two
types of responses (immediate and delayed) have been char-
acterized. The immediate responses are mostly limited toentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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repertoires and upregulation of MHC class I expression [3].
The delayed response consists of increased protein synthe-
sis, induction of Fas signaling, upregulation of costimula-
tory molecules and induction of adhesion molecules [4].
These changes at the radiated tumor site can significantly
affect the action of immune cells which are already present
or which will be recruited to the tumor site following im-
munotherapy. The main challenge for an efficacious com-
bination therapy is the determination of the optimum dose
and schedule which should result in a synergistic effect and
avoid negative events such as killing of the radiosensitive
immune cells. Because the majority of the radiation in-
duced immunological changes at the tumor site are
only transient it would be desirable to combine radi-
ation with immunotherapy to induce sustained memory
responses against different antigens and to mediate
long-lasting tumor protection. Moreover, while radi-
ation therapy is successfully used to treat single, small
and spatially well-defined tumors, it is not suitable for
the systemic treatment of non-symptomatic metastatic
disease. Thus, combining radiation therapy with immuno-
therapy, which induces systemic responses, should be
advantageous.
We have previously shown that mRNA-based two-
component cancer vaccines consisting of free and
complexed mRNA induce sustained, balanced immune
responses and mediate strong tumor protection in vivo,
thus represent a novel promising approach to cancer
therapy [5]. Here, we demonstrate that both therapies
(systemic mRNA immunotherapy and local tumor ir-
radiation) act synergistically to eradicate established
macroscopic E.G7-OVA and LLC tumors. Moreover, the
molecular and cellular analyses of the changes that occur at
the tumor sites give us an insight into the mechanisms in-
volved. Our data demonstrate that the induction of mech-
anistic changes in the tumor microenvironment, combined
with a potent immunotherapy, may lead to the significant
advances in the fight against cancer.
Material and methods
Material
Protamine was obtained from Valeant Pharmaceuticals
Germany GmbH (Germany). Following antibodies were
purchased from eBioscience (Germany): anti-NK1.1-PerCP-
Cy5.5 (clone PK136), anti-CD4-APC (clone RM4-5), anti-
CD11c-APC (clone N418), anti-CD8-PE-Cy7 (clone 53-6.7)
and anti-F4/80-APC-eFluor780 (clone BM8). Anti-CD11b-
PE-Cy7 (clone M1/70), anti-CD3-APC-Cy7 (clone 145-2C11)
and anti-CD45.2-HV450 (clone 104) were obtained from
BD Bioscience (Germany). SIINFEKL and control peptides
were purchased from Bachem AG (Germany). Collagenase
type IV was obtained from Sigma-Aldrich (Germany) and
DNAse I from Roche (Germany).RNActive® technology
CureVac GmbH proprietary technology generates mRNA
molecules with increased stability and translatability
(claimed in the patents: EP 1392341 and EP 1604688).
All mRNA vaccines used in this study were produced
according to this technology.
Two-component mRNA vaccine
mRNA was protamine-formulated as described previously
[5]. Briefly, the vaccine consists of a mixture of 50% free
mRNA (component 1) and 50% mRNA complexed with
protamine at a weight ratio of 2:1 (component 2). First,
mRNA was complexed by addition of protamine-Ringer
lactate solution and after stable complexation free
mRNA was added.
Mice and cell lines
C57BL/6 mice (7 - 9 weeks old) were purchased from
Janvier Laboratories (France). All experimental procedures
were performed in compliance with protocols approved by
the commission of the Regierungspraesidium Tuebingen.
EL-4 T cell lymphoma and E.G7-OVA, a mouse T cell
lymphoma cell line stably expressing Gallus gallus
Ovalbumin (GgOVA), were purchased from LGC Promo-
chem GmbH (Germany). A mouse Lewis lung carcinoma
(3LL-GFP cell line stably expressing Aequorea victoria green
fluorescence protein (GFP)), was a gift from B. Wielockx,
University Hospital/Faculty of Medicine Carl Gustav Carus
at the Technische Universität Dresden.
Tumor challenge
Mice were transplanted subcutaneously (s.c.) with either
E.G7-OVA (3×105 or 5×105) cells or 3LL-GFP (5x105)
cells for therapeutic vaccination and 1×106 E.G7-OVA
for prophylactic vaccination. Tumor growth was monitored
over time by measuring tumor size in 3 dimensions
using calipers. Tumor volume was calculated using fol-
lowing formula: Tumor volume (mm3) = (length (mm) ×
π × width2 (mm2))/6.
Vaccination
For prophylactic vaccination, mice were anesthetized
and vaccinated twice with 7-day interval. Animals were
challenged one week later. For therapeutic vaccination,
mice were inoculated with tumor cells and left un-
treated till the tumor reached the volume indicated in
the Figure legends. At that time, mice were anesthetized and
injected with mRNA vaccine (8 or 16 μg per injection site as
indicated; 4 injection sites/mouse distributed at the lower
and upper back). Untreated animals served as a control.
Irradiation
For radiation experiments, mice were transplanted s.c.
with tumor cells into the right hind limb and tumors
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room temperature using a linear accelerator (LINAC SL25,
Phillips) with a dose rate of 4 Gy/min. Local irradiation
of tumors was performed on 3-4 consecutive days with
different doses with or without combination with mRNA
vaccination as stated in the Figure legends. Only tumor
site was irradiated, the remaining body parts, including
vaccination sites, were covered by a shield.
qRT-PCR
Total RNA was extracted from explanted tumors using
the Qiagen RNeasy Mini Kit according to the manufac-
turer’s instruction. Expression levels of GgOVA were
quantified via RT-PCR by Biolytix AG (Switzerlad), using
mGAPDH as a reference gene. All reactions were per-
formed in triplicates.
Enzyme-linked immunosorbent spot
Splenocytes were isolated 6 days after the last vaccin-
ation. Splenocytes from mRNA-vaccinated and control
mice were stimulated with 1 μg/ml of either relevant
(SIINFEKL for OVA-vaccinated or EGFR-peptide library
for EGFR-vaccinated mice) or control MHC class I restricted
peptides. Secreted IFNγ was detected using a standard
ELISpot protocol and measured using a plate reader
(Immunospot Analyzer, CTL Analyzers LLC).
Microarray analysis
20 days after tumor challenge mice were euthanized;
complete tumors were excised and stored in RNAlater
RNA Stabilization Reagent (QIAGEN, Germany). Total
RNA was extracted by homogenization with RNeasy
isolation kit (QIAGEN, Germany) according to the manu-
facturer’s protocol. 10 μg purified RNA were used for
microarray analysis. RNA integrity and quantity was eval-
uated on Bioanalyzer-2100 (Agilent Technologies). Gene
expression analysis was performed by MFTServices
(Tübingen, Germany) via whole-genome RNA microarray
(Affymetrix, UK) and analyzed with Ingenuity IPA Software
(INGENUITY Systems, USA).
Flow cytometic analysis
For flow cytometric analysis of tumor infiltrating immune
cells, mice were euthanized, complete Lewis Lung tumors
were excised and a single cell suspension was generated via
30 min collagenase digestion at 37°C followed by tissue dis-
section with the gentleMACS (Miltenyi Biotech, Germany).
Single cell suspension was stained for CD45.2 to distinguish
between CD45.2- tumor cells and CD45.2+ host-derived
immune cells. The following immune cell populations
were further characterized: CD3+CD4+ T helper cells,
CD3+ CD8+ cytotoxic T lymphocytes, CD3+ NK1.1+
NKT cells, CD3- NK1.1+ NK cells, CD11c+ dendritic cells,CD11b+ F4/80+/- myeloid cells. Data were analyzed using
FlowJo software (TreeStar, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software, Version 5.01. The differences between groups
were analyzed using t-test or Mann-Whitney test, depend-
ing on the data distribution. Tumor growth was shown as
mean ± SEM. Analysis of grouped data was performed using
2-way ANOVA with Bonferroni posttests. Survival curves
were analyzed using Log-rank (Mantel-Cox) Test.
Results
mRNA-based cancer vaccines induce high frequencies of
antigen-specific T cells and mediate tumor protection
during prophylactic and therapeutic treatment
To demonstrate the potential of two-component mRNA-
based cancer vaccines to mount strong immune responses,
we vaccinated mice twice with a vaccine encoding the
model antigen ovalbumin (OVA). Six days after the boost
vaccination, high frequencies of OVA-specific T cells were
detected in the splenocytes of vaccinated mice (Figure 1A).
Moreover, prophylactic immunization with the OVA-
encoding vaccine significantly delayed the growth of
E.G7-OVA tumors (Figure 1B). Interestingly, qRT-PCR
analysis of escaping tumors revealed a complete loss of
OVA expression in the recurring tumors. These data
suggest that the vaccination enhanced tumor surveillance
resulting in the tumor outgrowth due to either antigen
loss or the selection of OVA-negative cells (Figure 1C).
Next, we tested the efficacy of the mRNA-based OVA vac-
cine in treating small, established tumors. We showed that
despite the very limited time window for the induction of
the immune response, frequent vaccination with two in-
jections per week was able to induce a statistically signifi-
cant delay in tumor growth compared to control animals
(p = 0.0091) (Figure 1D). However, the effect was less pro-
nounced compared to the prophylactic treatment. In sum-
mary, our results show that our two-component mRNA
vaccine induces strong protective immunity and delays
tumor growth in therapeutic settings.
mRNA vaccination and radiation therapy act synergistically
to facilitate the eradication of large established tumors and
mediate protection against re-challenge with parental
tumor cells
Therapeutic vaccines alone are not effective in curing
bulky, large tumors due to the time required to induce
a potent immune response as well as tumor-mediated
inhibitory mechanisms. We, therefore, asked whether
the combination of RNA immunotherapy with local ir-
radiation could result in the successful treatment of the
established tumors. E.G7-OVA tumor cells were trans-
planted subcutaneously into the right limb and mice were
BA
C D
Figure 1 Efficacy of RNA immunotherapy is strongly dependent on the tumor burden and time available for the induction of immune
response. (A) C57BL/6 mice (n = 5 per group) were vaccinated 2 times (1 vaccination/week) either with OVA mRNA vaccine (32 μg) or buffer.
After 7 days splenocytes from vaccinated mice were analyzed for IFN-γ secretion in response to Ovalbumin- or Connexin-derived epitope using
an ELISpot assay. * - p = 0.0154 (B) C57BL/6 mice (n = 8 per group) were vaccinated 2 times (1 vaccination/week) either with OVA mRNA vaccine
(64 μg), control vaccine (64 μg) or buffer. 6 days after the second vaccination, mice were challenged subcutaneously with 1 × 106 syngenic
E.G7-OVA tumor cells. Tumor growth was monitored by measuring the tumor size in 3 dimensions using calipers. *** - p < 0.0001 (C) Expression
of Ovalbumin in tumors escaping the control of the immune system, following prophylactic vaccination, was analyzed. Total RNA was isolated
and OVA expression was quantified via qRT-PCR in relation to mGAPDH. ** - p = 0.0034 (D) C57BL/6 mice (n = 8 per group) were challenged s.c.
with 0.3 × 106 syngenic E.G7-OVA tumor cells on day 0. On day 3 mice were treated either with OVA vaccine (32 μg), control vaccine (32 μg) or
buffer. Tumor growth was monitored by measuring the tumor size in 3 dimensions using calipers. ** - p = 0.0091, ***- p < 0.001, ****- p < 0.0001.
All presented data show representative results of at least two independent experiments.
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150 mm3. Since immunotherapy and radiation therapy
can successfully treat high percentage of small tumors, the
large tumor size as well as the delayed start of the therapy
was chosen to enable demonstration of the synergistic
effect of radioimmunotherapy in the settings when nei-
ther of the monotherapies was sufficient. Tumors of
mice in the radiation and the combined radioimmu-
notherapy groups were irradiated with a total dose of 6
Gy, administered in 3 equal fractions for three consecutivedays. Mice in the immunotherapy and the radioimmu-
notherapy groups received two vaccinations per week
starting at the first day of radiation. Immunotherapy
alone showed only a marginal effect on tumor growth
(Figure 2A), which was expected due to the limited time
during which an immune response can develop while tu-
mors are in the exponential growth phase. Similarly, radi-
ation alone induced only a transient inhibition of tumor
growth for about 7 days. In contrast, combined radioim-




Figure 2 Combination of RNA immunotherapy with radiation allows for the eradication of large established tumors and induction of
epitope spreading. (A) C57BL/6 mice (n = 8 per group) were challenged subcutaneously on the right limb with 0.3 × 106 syngenic E.G7-OVA
tumor cells. 13 days after tumor challenge (at a median tumor volume of 150 mm3) mice were treated either with OVA mRNA vaccine (32 μg),
radiation (6 Gy total, divided into 3 equal fractions on 3 consecutive days) or radioimmunotherapy as indicated (with first vaccination given 6h
before first radiation). Untreated mice served as a control. *** - p < 0.001 (B) Median survival time of mice analysed in Figure 2A. (C) C57BL/6 mice
(n = 8 per group) were challenged subcutaneously on the right limb with 0.5 × 106 syngenic E.G7-OVA tumor cells. 13 days after tumor challenge
(at a median tumor volume of 300 mm3) mice were treated either with local radiation (8 Gy total, divided into 4 equal fractions on 4 consecutive days)
or radioimmunotherapy as indicated (64 μg/vaccination, with first vaccination given 6 h before first radiation). Untreated mice served as a
control. ** - p < 0.01 (D) All complete responders, which were tumor free after combination therapy (day 106), were re-challenge
subcutaneously with 1 × 105 parenteral OVA-negative EL-4 cells. Tumor growth was monitored by measuring the tumor size in 3 dimensions
using calipers. All presented data show representative results of at least two independent experiments.
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pronounced tumor regression, resulting in complete and
sustained eradication of the tumor in 3 out of 7 mice.
Median survival in the combination group increased
significantly to 45 days after the start of treatment, com-
pared to 9 days for untreated mice (p = 0.0002), 11 days for
mice receiving immunotherapy (p = 0.0176) and 17.5 days
for mice receiving radiation therapy (p = 0.045) (Figure 2B).The efficacy of tumor treatment strongly depends on
the initial tumor burden. Therefore, to further determine
the potency of radioimmunotherapy in the next experi-
ment we challenged mice with a higher number of tumor
cells and investigated the effect of combination therapy on
larger tumors with a volume of about 300 mm3. A group
receiving vaccination alone was not included in this study
because we know that vaccination is not effective in mice
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ation dose to 8 Gy which was administrated in four equal
fractions for four consecutive days and increased the dose
of the OVA vaccine to 64 μg per vaccination. Mice were
vaccinated twice per week. We demonstrated that com-
bined radioimmunotherapy induced a strong synergistic
anti-tumor effect, resulting in significant tumor shrinkage
when compared to radiation treatment alone (Figure 2C).
Moreover, although both monotherapies resulted in an-
ecdotal complete responders, there was a high frequency
of surviving animals in the radioimmunotherapy treated
mice suggesting induction of a more effective immune
response within this group. To further characterize the
potency of the radioimmunotherapy we challenged the
surviving mice with the parental, OVA-negative EL4
tumor cells. As shown in Figure 2D majority of the
complete responders from radioimmunotherapy treated
group (5/7) survived the subsequent challenge with
parental tumor cells. Taken together, our data indicate
that combined radioimmunotherapy results in stronger
tumor growth retardation and greater survival compared
to each treatment modality alone.
Combined radioimmunotherapy is effective against low
immunogenic, radiation-resistant Lewis lung cancer
Having demonstrated the strong synergistic effect of radio-
therapy and mRNA immunotherapy in the treatment of
highly immunogenic E.G7-OVA tumors, we sought to de-
termine whether this therapeutic strategy is also effective
against one of the most challenging tumor models: LLC.
This tumor model is resistant to different kinds of thera-
peutic regimens (Avastin, radiation, adoptive T cell transfer)
[6-8]. It is characterized by nearly complete MHC class I
down regulation, a lack of known tumor rejection antigens,
very aggressive growth kinetics, frequent ulceration in small
tumors and rapid formation of spontaneous lung metasta-
ses from the primary solid tumor. We chose human EGFR
and Connexin as target antigens because of the evidence
for their immunogenicity [9]. As shown in Figure 3A,
application of the EGFR mRNA vaccine (5 vaccinations
in total, twice a week, 32 μg per vaccination) resulted
in a strong induction of EGFR-specific T cell responses
compared to control animals (p = 0.0036). In corrobor-
ation with the literature data [10] dose finding studies
revealed that LLC is strongly resistant to radiation
(Additional file 1: Figure S1). As shown in Figure 3B, to
achieve a weak and transient inhibitory effect on tumors
with a volume of just 50 mm3, a total dose of 36 Gy was
required. This dose was split into three fractions, given on
consecutive days, starting on day 18 after tumor challenge.
As shown in Figure 3B, immunotherapy alone was not able
to mediate any tumor growth inhibition and radiation
therapy alone resulted in only transient inhibition. In
sharp contrast, mRNA vaccines combined with a highdose of radiotherapy resulted in a strong synergistic
anti-tumor effect. In conclusion, our data show the ef-
ficacy of radioimmunotherapy in controlling tumor
growth of a low immunogenic carcinoma.
Radiation, immunotherapy and combined
radioimmunotherapy induce distinct changes in gene
expression at the tumor site
Immunotherapy or radiation therapy alone may be in-
sufficient to eliminate bulky tumors. However, our data
demonstrate the potency of a combined treatment. To
elucidate the mechanisms responsible for the synergis-
tic effects of RNA vaccines and local radiation, we first
compared the gene expression profiles from non-treated
control tumors and tumors from mice treated with either
immunotherapy or radiation alone. Additionally to gain
a mechanistic insight into the effect of radiation on im-
munotherapy we performed analyses to determine the
changes in gene expression following combination ther-
apy in comparison to vaccination alone. Mice were chal-
lenged with E.G7-OVA cells and were left untreated till
tumors reached a volume of about 150 mm3. Subse-
quently mice were treated with either radiation at a total
dose of 6 Gy applied for three consecutive days or/and
OVA-encoded mRNA vaccine. Seven days after the start
of treatment, 4 tumors per group were excised, total RNA
was extracted and gene expression analyzed. Differentially
expressed genes were identified by statistical analysis with
the p < 0.05 and a fold change of at least 1.5.
To exclude the effect of distinct tumor burdens, tumors
with similar volumes from the treated groups were chosen
for analyses. Despite comparable volumes, tumors exhibited
distinct gene expression profiles allowing for the correct
segregation of the single samples into the corresponding
treatment groups. As presented in Table 1 the analysis
revealed that a broad panel of genes, associated with
specific mechanistic pathways, was upregulated in the
radiated tumors. The most prominent functional pathways
upregulated after radiation were associated with angio-
genesis, adhesion, chemotaxis, antigen presentation, T
cell and NK signaling as well as with activation of the
complement system and Toll-like receptors. Interestingly,
immunotherapy alone also resulted in a pronounced
change at the tumor site. We detected a high number
of upregulated genes associated with T cell, NK cell,
TLR signaling, chemotaxis, antigen presentation and
activation of the complement system (Table 2). To elucidate
the molecular mechanism responsible for the synergistic
effects of the combination therapy we analyzed the gene
expression in the radiation and immunotherapy-treated
mice compared to the mice receiving vaccination only.
Interestingly, this analysis revealed that high number of
differentially regulated genes was downregulated (Table 3).
Many of these genes encoded for tumor associated factors
BA
C
Figure 3 Combination of RNA immunotherapy with radiation represents an effective treatment strategy for low immunogenic and
radioresistant LLC tumor. (A) C57BL/6 mice (n = 5 per group) were vaccinated 2 times (1 vaccination/week) either with EGFR mRNA vaccine
(32 μg) or with buffer. 7 days after completed vaccination splenocytes from vaccinated mice were analyzed for IFN-γ secretion in response to
EGFR- or Control-peptide library using an ELISpot assay. ** - p = 0.0036 (B) C57BL/6 mice (n = 10 per group) were challenged subcutaneously on
the right limb with 5 × 105 3LL-GFP cells. 18 days after tumor challenge mice were treated either with local radiation (36 Gy total, divided into 3
equal fractions on 3 consecutive days) or with radioimmunotherapy as indicated (with first vaccination given 6 h before second radiation).
Vaccination therapy without radiation started on day 14 post tumor challenge. Untreated mice served as a control. Tumor growth was monitored
by measuring the tumor size in 3 dimensions using calipers. (C) Median survival time of mice analyzed in Figure 3B.
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progression such as matrix metallopeptidases. In con-
trast, a number of genes described as tumor suppressors
(among them osteoglycin, dermatopontin and secreted
frizzled-related protein 4) were significantly upregulated
after combination therapy. In conclusion, our data show
induction of a unique gene signature following radioim-
munotherapy, which is distinct from radiation or vacci-
nation treatment alone, indicating a qualitative difference
in the combined therapy.Analysis of LLC tumors reveals an improved infiltration of
immune cells following combination therapy
Gene expression analysis revealed a number of sub-
stantial and specific changes at the tumor sites follow-
ing different therapies. Next, we asked whether these
changes are reflected in the cellular composition of the
tumor tissue. To obtain this information, we analyzed
LLC tumor infiltrates by flow cytometry. LLC tumor
cells were transplanted subcutaneously into the right
limb and mice were left untreated until the tumor
Table 1 Genes upregulated upon radiation
Pathway/function Genes upregulated upon tumor radiation
T cell signaling Cd8b1 (2.8), Cd8a (2.6), Il12r (2.2), Il2r (2.1), Gzmb (3.8), Gzmk (1.9), Prf1 (2.2), Icos (2.4),
Ctla4 (1.4), Eomes (1.6), Stat1 (1.6), Stat4 (2.4)
NK cell signaling Klrd1 (3.1), Klrk1 (2.1), Klrc1 (3.0), Klra2 (1.6), Nkg7 (4.0), Il12r (2.2), Gzmb (3.8), Gzmk (1.9), Prf1 (2.2), Fcgr4 (2.2)
Chemotaxis Ccl3 (2.0), Ccl5 (2.5), Ccl8 (2.1), Ccl11 (2.2), Cxcl12 (1.6), Cxcl16 (2.1), Ccrl2 (2.1), Ccr5 (1.7), Cxcr3 (1.5)
TLR signaling Tlr7 (1.9), Tlr8 (2.2), Tlr9 (1.6), Tlr13 (1.7), Irak3 (1.5), Aebp1 (2.5)
MHC class II presentation H2-Dma (1.8), H2-Ab1 (1.7), H2-Eb1 (1.5), H2-Aa (1.9), H2-T24 (1.8), Cd74 (1.7), Cathepsins:
k, s, c, h, w, a (1.6-2.0), Anpep (1.9)
Complement system C1qa (2.0), C1qb (1.6), C1qc (2.1), C1r (1.7), C2 (2.2), C3 (2.0), C4b (2.6), Cfb (2.1), Cfh (1.9)
Dendritic cells, macrophages Cd11c (Itgax) (1.9), Cd11b (Itgam) (1.7), Clec4a1 (2.1), Clec4a3 (2.2), Ly6i (2.3), Sema4 (1.9),
Blnk (1.6), Lrp1 (2.6), Aebp1 (2.5), Nos2 (2.4)
Adhesion Vcam1 (1.8), Lamc1 (1.8), Tns1 (1.8), Cd38 (1.8), Itgam (1.7), Itgax (1.9), Thbs1 (1.5), Thbs2 (2.2),
Clec4a1 (2.1), Clec4a3 (2.2), Antxr (2.6)
Angiogenesis Ecm1 (2.1), Ptafr (1.6), Hpse (2.1), Atxr1 (2.6), Fgfr1 (1.6), Mmp13 (4.1), Mmp19 (1.7), Thbs1 (1.5),
Nrp2 (1.8), Nrp1 (2.4), Crim1 (1.5), Ace (2.1), Plxdc2 (1.8)
C57BL/6 mice (4 mice per group) were challenged s.c. on the right limb with 3 × 105 syngenic E.G7-OVA tumor cells. Mice were treated starting at day 13 with
local radiation of 6 Gy applied in 3 equal doses on 3 consecutive days. Untreated mice served as controls. After 7 days tumors were exercised, RNA was isolated
and gene expression was analyzed. Differentially expressed genes were identified by statistical analysis with the p ≤ 0.05 and a fold change of at least 1.5. The
exact fold change is presented in the brackets.
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ation (RTX alone) and the combined radioimmunotherapy
(RNA+ RTX) groups were irradiated with a total dose of
36 Gy, administered in 3 fractions of 12 Gy each on three
consecutive days. Mice in the immunotherapy (RNA alone)
and the radioimmunotherapy groups received two vac-
cinations per week. Untreated mice served as controls
(No therapy). On day 25, tumors were isolated and the
cellular composition was analyzed. At this time point,
tumors did not differ significantly in volume (median
volume was about 150-200 mm3). As shown in Figure 4A,
irradiation of LLC tumors led to a strong upregulation
of the MHC class I molecule. Additionally, the cellular
composition of the tumor microenvironment was dra-
matically changed after irradiation and combination
therapy compared to the untreated control tumors. As
shown in Figure 4B when different populations of theTable 2 Genes upregulated upon vaccination
Pathway/function Genes upregulated upon vaccina
T cell signaling Cd8b1 (2.4), Cd8a (2.3), Il12r (1.8), Il2
Icos (2.1), Nkg7 (3.5), Stat1 (1.6), Stat
NK cell signaling Klrd1 (2.4), Klrk1 (1.7), Klrc1 (2.9), Nkg
Chemotaxis Ccl3 (1.8), Ccl5 (2.7), Cxcl9 (1.9), Cxc
TLR signaling Tlr7 (2.2), Tlr8 (2.3), Tlr13 (1.8)
MHC class II presentation H2-Dma (1.6), H2-Eb2 (1.7), H2-Aa (1
Complement system C1qa (1.9), C1qb (1.7), C1qc (2.1), C1
IFN-γ inducible GTPases Gbp2 (2.2), Gbp3 (1.8), Gbp4 (1.8), G
C57BL/6 mice (4 mice per group) were challenged s.c. on the right limb with 3 × 10
three vaccinations of OVA-encoded mRNA (32 μg/mouse, 2x week). Untreated mice
gene expression was analyzed. Differentially expressed genes were identified by sta
fold change is presented in the brackets.tumor infiltrating immune cells were analyzed, we ob-
served that tumor radiation induced a strong increase
of myeloid and dendritic cells which are associated
with activation of innate immune system. This was also
the case for the combination therapy. Importantly,
compared to control mice tumors from mice treated
with combined immunoradiotherapy exhibited statisti-
cally significant increase in infiltration of CD4+, CD8+
T cells and NKT cells which are associated with the
adaptive immune system. Despite the late onset of the
immunotherapy also after vaccination alone improved
infiltration of CD8+ T cells (fold change 1.4) and CD4+
T cells (fold change 0.6) could be observed suggesting
beneficial effects of the immunotherapy even with the
high tumor burden. The frequency of B cells was very
low and levels did not change after the various treatments
(data not shown). Taken together, our results show thattion
r (1.6), Ifng (1.6), Gzmb (3.0), Gzmk (1.7), Prf1 (2.0),
4 (1.8)
7 (3.5), Il12r (1.8), Gzmb (3.0), Gzmk (1.7), Prf1 (2.0), Fcgr3 (1.5), Fcgr4 (1.9)
l12 (1.5), Cxcl16 (2.2), Ccr5 (1.6)
.8), Cd74 (1.6), Cathepsins: k,s,c,d,h,l,w,a (1.5-2.1), Lgmn (1.8)
r (1.9), C1s (2.7), C2 (2.6), C3 (2.1), C3ar1 (1.7), Cfb (2.7)
bp5 (2.0), Gbp6 (1.7)
5 syngenic E.G7-OVA tumor cells. Mice were treated starting at day 13 with
served as controls. After 7 days tumors were exercised, RNA was isolated and
tistical analysis with the p ≤ 0.05 and a fold change of at least 1.5. The exact
Table 3 Genes differentially regulated upon combination therapy in comparison to vaccinated mice
Pathway/function Downregulated genes
Genes associated with tumor invasiveness Adam18 (6.7), Adam9 (1.6), Tgfbi (1.7), Mmp12 (1.8), Mmp3 (2.0), Mmp10 (2.2), Slc7a2 (2.4)
Tumor associated factors Ly6i (3.1), Lrrc15 (2.4), Mamdc2 (2.4), Tm2d2 (2.1), Gpr97 (2.3), Grem1 (2.5), Dok4 (2.4),
Tacc1 (2.3), Inhba (2.0), Ifitm1 (2.4)
Pathway/function Upregulated genes
Genes associated with tumor suppresion Phlda1 (2.3), Cxcl14 (2.4), Cd209a (2.4), Timp1 (1.9), Sfrp4 (3.9), Sulf1 (1.8), Nr1d1 (1.8),
Ogn (5.0), Scara3 (2.3), Dpt (5.0)
C57BL/6 mice (4 mice per group) were challenged subcutaneously on the right limb with 3 × 105 syngenic E.G7-OVA tumor cells. Mice were treated with the
radioimmunotherapy starting at day 13 (local radiation of 6 Gy applied in 3 equal doses on 3 consecutive days and three vaccination with OVA-encoded
mRNA – 32 μg, 2x week). OVA-encoded mRNA vaccinated mice served as controls. After 7 days tumors were exercised, RNA was isolated and gene expression was
analyzed. Differentially expressed genes were identified by statistical analysis with the p ≤ 0.05 and a fold change of at least 1.5. The exact fold change is
presented in the brackets.
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http://www.ro-journal.com/content/9/1/180local radiation of large established tumors results in cel-
lular changes in the tumor microenvironment, making the
tumor more accessible to mRNA-based immunotherapy.
Discussion
Since the initial discovery of the tumor associated anti-
gens (TAAs), which make cancer cells a potential target
of the immune system, the efforts has been focused on de-
signing therapies to induce potent and specific anti-tumor
immune responses. This, together with the increased know-
ledge of the tumor biology, has resulted in the substantial
progress made in recent years and has enabled immuno-
therapy to become promising strategy for cancer treatment
[11]. An increasing amount of preclinical and clinical
data underlines the therapeutic potential of combined
anti-cancer approaches (reviewed in [12]). Here, we showed
that two-component mRNA vaccines can be combined
with local tumor irradiation to give a strong synergistic
anti-tumor effect, even against low immunogenic LLC
tumors. 3LL-GFP cell line used in our studies was charac-
terized by an aggressive tumor growth suggesting lack of
the rejecting responses generated against GFP protein. This
stays in agreement with data provided by Skelton et al.
showing minimal immunogenicity of GFP in C57BL/6 mice
contrary to Balb/c strain [13]. In addition, we demonstrated
that combination therapy results in the complete eradica-
tion of large established E.G7-OVA tumors with a size of
ca. 150 mm3 in a significant number of mice for which
monotherapies were mostly ineffective. The remaining mice
exhibited a delayed tumor growth. In our quest to better
understand the synergistic effects of radioimmunotherapy
we analyzed the effects of radiation on the gene expression
in comparison to mice which received vaccination only.
Combination therapy showed the upregulation of some
interesting genes coding for tumor suppressor proteins.
Concomitantly, genes coding for the proteins described
as tumor associated factors or molecules promoting
tumor invasion were downregulated. The flow cytomet-
ric analysis of tumors treated with combination therapy
versus monotherapy, revealed an increased infiltration
of cells associated with the activation of the adaptiveimmune system. LLC tumors are known for their strong
immunosuppressive properties; therefore immunotherapy
of already established tumors with the volume between
50-100 mm3 cannot inhibit the tumor escape. Notably,
the activation of immune system has occurred as dem-
onstrated by the improved CD8+ T cell infiltration
(compared to the control mice) followed the vaccin-
ation alone. Interestingly, vaccination alone tended to
decrease frequency of regulatory T cells (Tregs) within
the tumor whereas radiation exhibited the opposite ef-
fect as previously shown [14]. More importantly, this in-
crease was not detectable in the combination treatment
group further suggesting beneficial effect of the vaccin-
ation (Additional file 1: Figure S2). Taken together, our
data provide evidence that the combination of immuno-
therapy with local tumor irradiation creates an immune
response which results in efficient tumor treatment.
mRNA vaccines in combination with irradiation, generate
a different immune response compared to the monother-
apies alone. This can be seen in the gene expression pro-
file of tumors treated with the combination therapy,
which show a completely different gene expression pattern
to the monotherapies. The downregulation of peptidases,
responsible for the degradation of extracellular matrix and
for tumor invasion, was only observed in mice treated
with the combination therapy. Interestingly, some genes
coding for tumor suppressors were only upregulated in
the group treated with radioimmunotherapy. The secreted
frizzled-related protein 4 (SFRP4), proposed as a tumor
suppressor in many cancers based on its loss in patients’
tumors [15], was upregulated about 4 fold in mice treated
with the combination therapy. Jacob et al. reported that
the loss of SFRP4 correlates with an aggressive phenotype
and predicts poor outcome in ovarian cancer patients
[16]. Moreover they postulated a role for SFRP4 as a
tumor suppressor gene in ovarian cancers via inhib-
ition of the Wnt signaling pathway. Dermatopontin
(DPT), another gene strongly upregulated by the com-
bination therapy, codes for a tumor suppressor. Li and
colleagues showed that DPT is expressed in human
liver and is significantly downregulated in hepatocellular
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Figure 4 Infiltration of immune cells into the large established immunosuppressive LLC tumors is improved after combination therapy.
C57BL/6 mice (n = 4 per group) were challenged subcutaneously on the right hind limb with 5 × 105 3LL-GFP cells. 18 days after tumor challenge
mice were treated with local radiation alone (36 Gy total, divided into 3 equal fractions on 3 consecutive days) (RTX alone), vaccination alone
(32 μg, twice a week, started at day 18) (RNA alone) or with radioimmunotherapy (with first vaccination given on day 19) (RNA + RTX). Untreated
mice served as a control (No therapy). On day 25 tumors were excised, homogenized and immune cell infiltration analyzed by flow cytometry.
(A) MHC class I expression was analyzed on single cell suspension of untreated- and irradiated tumor cells. (B) CD45.2+ host-derived immune cells
were characterized by cell surface staining of several lineage markers and the ratio of different CD45.2+ immune cell subpopulations to CD45.2- tumor
cells is shown as median of four animals per group. * p < 0.05. Presented data show representative results of two independent analyses.
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http://www.ro-journal.com/content/9/1/180carcinoma. Its loss is postulated to be associated with
carcinogenesis [17]. Recent work from Yamatoji et al.
described DPT as a potential predictor for metastasis
of human oral cancer [18]. They showed that DPT ex-
pression in primary oral squamous cell carcinoma cells
was significantly lower than in normal counterpartsand correlated with regional lymph node metastasis.
The authors postulated that downregulation of DPT is
a characteristic event in oral squamous cell carcinoma
and that this protein might play an important role in
regulating tumor invasion and metastasis [18]. We also
found that the osteoglycin gene (ogn) was upregulated
Fotin-Mleczek et al. Radiation Oncology 2014, 9:180 Page 11 of 13
http://www.ro-journal.com/content/9/1/1804.6 fold in mice treated with the combination therapy.
Its downregulation is also described as a diagnostic
protein marker in squamous cervical cancer [19]. In
summary, the strong upregulation of tumor suppressor
genes found in the group treated with immunotherapy
and radiation underlines the clinical relevance and
therapeutic potential of the combination therapy.
The increased frequency of mice which survived E.G7-
OVA tumor challenge in the combination group compared
to the monotherapy groups is another indication of the
distinct immune response induced by mRNA vaccine/
irradiation therapy. Furthermore, majority of mice that
remained tumor-free after E.G7-OVA tumor challenge
survived subsequent challenge with the parental EL-4.
This suggests a possible induction of memory T cells,
which are able to recognize other tumor-associated an-
tigens besides the specific one used in the vaccination.
The induction of broad immune protection against
antigen-negative tumors is highly desirable and can be
achieved via induction of epitope spreading. Reits et al.
showed in the murine colon adenocarcinoma that radiation
can modulate the peptide repertoire, by expanding the
intracellular peptide pool [3]. Additionally, Nesslinger et al.
tested a poxvirus-based vaccine encoding prostate-specific
antigen (PSA) with radiotherapy in patients with localized
prostate cancer. They could show that vaccination against
PSA, combined with external beam radiation therapy, in-
duced immune responses to additional tumor-associated
antigens. The epitope spreading was observed in a large
number of patients treated with vaccine and radiation
[20]. Similar results were obtained by Gully and colleagues
in a phase II clinical trial. They observed that the combin-
ation of a poxviral vaccine encoding PSA with radiotherapy,
induced not only a PSA-specific T-cell response in patients
with clinically localized prostate cancer, but also showed
evidence of de novo generation of T cells with specificity for
different antigens [21]. With these encouraging re-
sults, further clinical trials have been initiated to test
the safety and clinical efficacy of radioimmunotherapy
(e.g. clinical trial NCT00450619 – testing combination
of Prostvac with radiotherapeutic Quadramet in pros-
tate cancer or clinical trial NCT00085241, in which
CEA-TRICOM was combined with local radiation of
liver metastases). Also at the preclinical stage, the positive
impact of radiation together with vaccination/anti-CD25
mAb regimen in the elimination of established tumors
was shown, suggesting a possible broad application of this
combination therapy [22].
An important role of ionizing radiation is its ability
to modify the tumor microenvironment, thus limiting
immunosuppressive capacity and enabling efficient
homing of immune cells to the tumor [3]. It has been
previously shown that CXCL16 is responsible for attract-
ing tumor-specific T cells to the irradiated tumor site [23]and is a crucial component of the successful combination
of radiotherapy and anti-CTLA4 treatment in a mouse
breast cancer model [24]. In our study we also observed the
induction of CXCL16 following radiation therapy (Table 1).
Tumor vasculature is characterized by downregulation
of adhesion molecules which decreases the ability of T
cells to home to the tumor site [25]. Our data show
that radiation can increase the expression of vascular
cell adhesion molecule (VCAM)-1, a phenomenon which
was also observed by others [26]. This could also contribute
to the enhanced trafficking of immune cells to the tumor
site and their retention there. In addition, we observed in-
creased infiltration of CD11b+ and CD11c+ cells following
both irradiation and the combined treatment (Figure 4).
The role of macrophages, the biggest cell subset expressing
CD11b marker, in the immune response is controversial.
However, Kawai et al. showed that an increase in these cells
in cancer nests of NSCLC after chemotherapy is a positive
prognostic predictor of patients’ survival [27]. Of note,
further characterization of the tumor-infiltrating myeloid
cells revealed increased frequencies of myeloid derived sup-
pressor cells (MDSCs) following radiation treatment as pre-
viously described [28]. However, addition of vaccination did
not further enhance this population with vaccination alone
having a beneficial effect on the numbers of MDSCs within
the tumor (Additional file 1: Figure S3). In addition,
both macrophages and CD11c+ dendritic cells are re-
sponsible for the clearance of irradiation-induced dead
or damaged tissues followed by antigen presentation
and T cell activation [29,30]. It is therefore of interest
that both radiation and the combination therapy increased
tumor infiltration by cross-presenting CD8+ DCs
(Additional file 1: Figure S4). A positive correlation be-
tween improved survival and intratumoral dendritic
cells (DCs) has been shown in hepatocellular carcinoma
[31] and several lines of evidence demonstrate DCs par-
ticipation in anti-tumor immunity [32]. Moreover, both
microarray and flow cytometric data indicated an in-
crease in CD4+ and CD8+ T cells as well as NK cell infil-
tration. In accordance to the presented data, a positive
correlation between tumor-infiltrating T cells and favor-
able prognosis has been described in a variety of different
cancer types such as hepatocellular carcinoma [33], pan-
creatic carcinoma [34,35], lung carcinoma [36], colorectal
cancer [37,38] and melanoma [39].
In conclusion, our results demonstrate that tumor-
specific mRNA-based vaccines can be effectively combined
with standard cancer therapies, such as radiation to create
highly synergistic anti-tumor effects. We strongly believe
that the combination approaches will play central role
in the future clinical developments, opening the possibility
to attack tumors via complementary, synergistically acting
mechanisms and consequently improve long-term survival
of cancer patients.
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Additional file 1: Figure S1. LLC tumor growth after various radiation
doses. Figure S2. Infiltration of Lewis Lung Carcinoma tumors by Tregs
following various treatments. Figure S3. Infiltration of Lewis Lung
Carcinoma tumors by MDSCs following various treatments. Figure S4.
Infiltration of Lewis Lung Carcinoma tumors by CD8+ DCs following
various treatments. Figure S5. Gating strategy for analyzing tumor
infiltrating DCs.
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